KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Common Equity (2016 - 2025)

Rigel Pharmaceuticals has reported Common Equity over the past 16 years, most recently at $391.5 million for Q4 2025.

  • Quarterly results put Common Equity at $391.5 million for Q4 2025, up 11806.33% from a year ago — trailing twelve months through Dec 2025 was $391.5 million (up 11806.33% YoY), and the annual figure for FY2025 was $391.5 million, up 11806.33%.
  • Common Equity for Q4 2025 was $391.5 million at Rigel Pharmaceuticals, up from $117.6 million in the prior quarter.
  • Over the last five years, Common Equity for RIGL hit a ceiling of $391.5 million in Q4 2025 and a floor of -$31.8 million in Q3 2023.
  • Median Common Equity over the past 5 years was -$194500.0 (2022), compared with a mean of $31.0 million.
  • Biggest five-year swings in Common Equity: crashed 664.62% in 2023 and later skyrocketed 11806.33% in 2025.
  • Rigel Pharmaceuticals' Common Equity stood at $30.4 million in 2021, then tumbled by 144.83% to -$13.6 million in 2022, then crashed by 110.37% to -$28.6 million in 2023, then soared by 111.48% to $3.3 million in 2024, then skyrocketed by 11806.33% to $391.5 million in 2025.
  • The last three reported values for Common Equity were $391.5 million (Q4 2025), $117.6 million (Q3 2025), and $81.9 million (Q2 2025) per Business Quant data.